Drugs / ABSK043
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04964375 | Aug 2021 → Oct 2022 | neoplasm | Abbisko Therapeutics Co, Ltd | Unknown | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07710612 | Aug 2026 → Dec 2029 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07164170 | Sep 2025 → Dec 2028 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07014137 | Sep 2025 → Mar 2027 expected | sarcoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT06978933 | Apr 2025 → Dec 2026 expected | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06668103 | Nov 2024 → Dec 2027 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06632262 | Nov 2024 → Nov 2029 expected | gastroesophageal cancer, non-small cell lung carcinoma, urothelial carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK043 | “ABSK043, is an orally available, selective and potent inhibitor targeting the interaction of PD-1 and PD-L1” NCT06978933 ↗ |
| Action | Inhibit | “ABSK043 is a novel, oral small molecule inhibitor of PD-L1” NCT04964375 ↗ |
| Modality | Small molecule | “ABSK043 is a novel, oral small molecule inhibitor of PD-L1” NCT04964375 ↗ |
| Route | Oral | “For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043” NCT04964375 ↗ |